Results 211 to 220 of about 74,284 (255)

Antibody-Drug Conjugate Targets

Current Cancer Drug Targets, 2009
The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire   +2 more sources

Payloads of Antibody: Drug Conjugates

2015
The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire   +1 more source

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Cortes J, Roberto Carmagnani Pestana   +2 more
exaly  

A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors

Molecular Therapy, 2022
Yu Ding, Yanling Wu, Cuicui Chen
exaly  

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Annals of Oncology, 2021
A D Santin, V Picozzi, J M Lang
exaly  

A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer

Drug Delivery, 2022
Xiujun Liu
exaly  

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

Neuro-Oncology Advances, 2023
Andrew Lassman, Benedito A Carneiro, Ryan Merrell   +2 more
exaly  

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

Expert Opinion on Biological Therapy, 2020
Robert Sharkey, David M Goldenberg
exaly  

Antibody drug conjugates

2022
XU HE, LEE HONG MYUNG, ARENDT CHRISTOPHER   +2 more
openaire   +5 more sources

Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice

Xenobiotica, 2020
Katsunobu Hagihara
exaly